A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Mar 2017

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Aripiprazole (Primary) ; Aripiprazole (Primary) ; Paliperidone; Paliperidone
Indications Schizophrenia
Focus Registrational; Therapeutic Use
Acronyms QUALIFY
Sponsors Lundbeck A/S

01 Mar 2017 Resultsb of a post-hoc analysis evaluating the differential treatment effects of Aripiprazole once-monthly 400 mg (AOM 400) and paliperidone palmitate (PP) on sexual dysfunction and prolactin levels, published in the International Clinical Psychopharmacology.
08 Dec 2016 Results published in the International Journal of Neuropsychopharmacology.
20 Sep 2016 Results of a post-hoc analysis assessing effect sizes of aripiprazole and paliperidone palmitate in the treatment of schizophrenia, presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com